RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Armata Pharmaceuticals Stock

Armata Pharmaceuticals ROE 2025

Armata Pharmaceuticals ROE

2.15

Ticker

ARMP

ISIN

US04216R1023

WKN

A2PKLC

In 2025, Armata Pharmaceuticals's return on equity (ROE) was 2.15, a -310.43% increase from the -1.02 ROE in the previous year.

Armata Pharmaceuticals Aktienanalyse

What does Armata Pharmaceuticals do?

Armata Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of therapies for severe bacterial infections. The company was founded in California in 2009 and has been listed on the NASDAQ stock exchange since 2019. The founders of Armata Pharmaceuticals Inc. recognized that antibiotic resistance is a growing problem and that it is crucial to develop new therapies to address the challenges in the fight against bacterial infections. The company's business model is based on the discovery and development of bacteriophage therapies. Bacteriophages are natural viruses that can infect and destroy bacteria. Armata Pharmaceuticals Inc. has two main divisions: Armatavax, which focuses on the development of vaccines against bacterial infections, and Armatamab, which works on the development of monoclonal antibodies that express bacteriophage genes and thus have higher efficacy in combating bacteria. The company is currently developing several products based on bacteriophage therapies. The main product is AR-301, a monoclonal antibody designed to treat Staphylococcus infections causing pneumonia. AR-301 is in phase IIb study and has shown promising results. The company also has several other products in the pipeline, including AR-105 against Pseudomonas aeruginosa infections, AR-201 against Acinetobacter baumannii infections, and AR-401 against Enterobacteriaceae infections. Armata Pharmaceuticals Inc. works closely with various academic institutions and research facilities to explore the potential of bacteriophage therapies and develop new products. The company has acquired a number of patents and intellectual property in this area. To bring its products to market, Armata Pharmaceuticals Inc. has formed strategic partnerships with various companies, including AmpliPhi Biosciences, the United States Department of Defense's Drug Agency (DTRA), and Synthetic Biologics. These partnerships enable the company to lower its development costs while increasing access to a broader market. In summary, Armata Pharmaceuticals Inc. is an innovative biopharmaceutical company specializing in the development of bacteriophage therapies for severe bacterial infections. The company has a strong pipeline of products in various stages of development and is actively working to improve its technology and strengthen its market position. Through its partnerships and commitment to cutting-edge research, Armata Pharmaceuticals Inc. ensures that it is well-positioned to address the challenges in the fight against antibiotic resistance. Armata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Armata Pharmaceuticals's Return on Equity (ROE)

Armata Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Armata Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Armata Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Armata Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Armata Pharmaceuticals stock

What is the ROE (Return on Equity) of Armata Pharmaceuticals this year?

The ROE of Armata Pharmaceuticals this year is 2.15 undefined.

How has the Return on Equity (ROE) of Armata Pharmaceuticals developed compared to the previous year?

The ROE of Armata Pharmaceuticals has increased by -310.43% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Armata Pharmaceuticals?

A high ROE indicates that Armata Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Armata Pharmaceuticals?

A low ROE can indicate that Armata Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Armata Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Armata Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Armata Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Armata Pharmaceuticals?

Some factors that can influence Armata Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Armata Pharmaceuticals pay?

Over the past 12 months, Armata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Armata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Armata Pharmaceuticals?

The current dividend yield of Armata Pharmaceuticals is .

When does Armata Pharmaceuticals pay dividends?

Armata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Armata Pharmaceuticals?

Armata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Armata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Armata Pharmaceuticals located?

Armata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Armata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Armata Pharmaceuticals from 1/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/29/2025.

When did Armata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/29/2025.

What was the dividend of Armata Pharmaceuticals in the year 2024?

In the year 2024, Armata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Armata Pharmaceuticals pay out the dividend?

The dividends of Armata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Armata Pharmaceuticals

Our stock analysis for Armata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Armata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.